Translational Drug Development (TD2)
Business Services · Arizona, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
13208 E Shea Blvd Ste 100, Scottsdale, A...Phone Number
(602) 358-8300Website
www.td2inc.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About Translational Drug Development (TD2)
TD2 Oncology is a leading oncology contract research organization (CRO) that specializes in advancing oncology research by guiding new therapies from preclinical stages through clinical trials to FDA approval. The company offers a comprehensive suite of services including clinical trial design, regulatory support, and advanced flow cytometry, catering to biotech and pharmaceutical companies. With a focus on innovative cancer therapies, TD2 utilizes over 400 cancer models and a collaborative approach to ensure successful outcomes. Their mission is to accelerate the development of cancer treatments through strategic partnerships and a highly specialized team.Explore more
Translational Drug Development (TD2) Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Translational Drug Development (TD2) your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Translational Drug Development (TD2)
Earning: See what the market has to say on Translational Drug Development (TD2) recently announced quarterly report
Product Launch: Get notified when Translational Drug Development (TD2) launches new products
Funding: Get notified immidiatlly once Translational Drug Development (TD2) has new funding data
Translational Drug Development (TD2), which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Translational Drug Development (TD2) is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Translational Drug Development (TD2) has recently received funding, and reach out quickly before it becomes old news!
Click to see if Translational Drug Development (TD2) had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Translational Drug Development (TD2)
Compare insights from companies similar to Translational Drug Development (TD2), focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Translational Drug Development (TD2) is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Translational Drug Development (TD2) is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Translational Drug Development (TD2).
Translational Drug Development (TD2) Tech Stack
A closer look at the technologies used by Translational Drug Development (TD2)
Most Recent Scoops
Open Position
Hiring Plans
Translational Drug Development (TD2) has more open roles in Medical & Health than it has had at any time in the past 12 months.
Hiring Plans
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Open Position
Translational Drug Development (TD2) News & Media
Translational Drug Development (TD2) Expands Clinical Trial Services into Europe
SCOTTSDALE, ARIZONA, UNITED STATES, September 4, 2024 /EINPresswire.com/ -- Translational Drug Development (TD2), a leading provider of comprehensive preclinical drug development, translational and clinical trial services, announces the formation of a …Atropos Evidence™ Network Grows to Over 300 Million Patients - Becoming Industry’s Largest Federated Healthcare Data Network - and Announces Additional Customer
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health today announced the expansion of the Atropos Evidence Network to include two new partners, adding to the growing number of datasets and use cases for the Atropos Evidence Network including oncology and international. The company additionally announced a new customer - Translational Drug Development (TD2) - which will gain immediate access to clinical insights generated from Atropos Health’s new data contributors. The Atropos Evidence Network exTD2 to Present Precision Preclinical Applications for Glioblastoma and Non-Small Cell Lung Cancer at AACR Annual Meeting
Three Poster Presentations Highlight Novel Data SCOTTSDALE, ARIZONA, UNITED STATES, April 3, 2024 /EINPresswire.com/ -- Translational Drug Development (TD2), a precision oncology contract research organization (CRO), announces the presentation of their …TD2 Expands Preclinical and Clinical Services by Acquiring Flow Contract Site Laboratory (FCSL)
Strengthening its Translational Oncology Ecosystem SCOTTSDALE, ARIZONA, USA, February 1, 2024 /EINPresswire.com/ -- Translational Drug Development (TD2), a leading provider of comprehensive preclinical drug development, translational and clinical trial …
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Translational Drug Development (TD2)
Sign Up For FreeTo access detailed company insights
TD2 Oncology is a leading oncology contract research organization (CRO) that specializes in advancing oncology research by guiding new therapies from preclinical stages through clinical trials to FDA approval. The company offers a comprehensive suite of services including clinical trial design, regulatory support, and advanced flow cytometry, cater... Read More
